Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin

Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin

Aim. To compare the effect of 12-month pharmacotherapy with a betablocker (BB) (bisoprolol and nebivolol) and a combination of BB with a mineralocorticoid receptor antagonist (bisoprolol+eplerenone, nebivolol+eplerenone) on following fibrosis markers: matrix metalloproteinases 1 and 9 (MMP-1, MMP-9)...

Full description

Bibliographic Details
Main Authors: O. A. Osipova, E. V. Gosteva, T. P. Golivets, O. N. Belousova, O. A. Zemlyansky, M. V. Pokrovsky, A. I. Golovin, N. V. Grigorenko, A. A. Merezhko
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2021-11-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
heart failure
myocardial fibrosis
beta-blockers
mineralocorticoid receptor antagonists
Online Access:https://cardiovascular.elpub.ru/jour/article/view/3068

Internet

https://cardiovascular.elpub.ru/jour/article/view/3068

Similar Items